Personalized Neoantigen Vaccines

✓ Medically reviewed | Published: | Evidence level: 1A
A review reported by Bioengineer.org concludes that personalized neoantigen vaccines can improve outcomes in early disease settings. These mRNA or peptide-based vaccines are built from a patient's own tumor mutations and are typically studied alongside immune checkpoint inhibitors, with larger trials still defining their role.
📅 Published:
✓ Reviewed by iMedic Medical Editorial Team
📄 Oncology

Quick Facts

Vaccine target
Tumor-specific mutations
Common platform
mRNA or peptide
Typical partner
Checkpoint inhibitors
Main setting
Early-stage, post-surgery

How do personalized neoantigen vaccines work?

Quick answer: They train the immune system to recognize mutation-derived proteins found only on a patient's tumor cells.

Cancer cells accumulate mutations, and some produce abnormal proteins called neoantigens that the immune system can recognize as foreign. To build a personalized vaccine, researchers sequence a patient's tumor and normal tissue, use computational tools to predict which mutations are most likely to trigger an immune response, and manufacture a vaccine encoding those targets. The vaccine, delivered as mRNA, peptides or other formats, aims to prime T cells to find and eliminate residual tumor cells.

Because each vaccine is tailored to one individual, manufacturing speed, cost and quality control are central challenges. The approach is conceptually different from standard preventive vaccines, as it is used to treat or prevent recurrence of an existing cancer rather than prevent infection.

What does the evidence show so far for early disease?

Quick answer: Early trials and reviews suggest benefit, especially when vaccines are added to checkpoint inhibitors after surgery, but larger phase 3 data are still needed.

Early-stage disease is considered an attractive setting because the tumor burden is low after surgery, and the immune system may be less suppressed than in advanced cancer. A randomized phase 2b trial in high-risk melanoma, reported by Moderna and Merck, found that adding the personalized mRNA vaccine intismeran autogene to pembrolizumab reduced the risk of recurrence or death compared with pembrolizumab alone, with the companies reporting a reduction of roughly 44 percent at the two-year analysis. Phase 3 trials are ongoing in melanoma and other tumor types.

The review highlighted by Bioengineer.org reflects this broader picture of encouraging signals, though trial sizes have often been modest and follow-up periods limited. Reviews of this kind can identify patterns but cannot replace confirmatory randomized trials, and results in one cancer type may not translate to others.

What are the limitations and what comes next?

Quick answer: Key hurdles include cost, turnaround time, identifying which patients benefit, and confirming survival gains in large trials.

Researchers are working to improve neoantigen prediction, since not every predicted target generates a strong immune response. Biomarkers such as circulating tumor DNA may help identify patients with minimal residual disease who are most likely to benefit, and combination strategies with other immunotherapies are being explored. Side effects reported in trials have generally been mild to moderate, such as fatigue and injection-site reactions, but long-term safety will continue to be monitored.

Patients interested in these approaches should discuss clinical trial eligibility with their oncology team. Access currently depends mostly on enrollment in studies, and approvals will rely on regulators reviewing phase 3 outcomes, including recurrence-free and overall survival.

Frequently Asked Questions

Personalized neoantigen vaccines are still primarily investigational, with phase 3 trials underway. Patients can usually access them through clinical trials.

A tumor sample is sequenced to identify mutations, algorithms select likely targets, and a custom vaccine is manufactured, a process that takes several weeks.

No. In studies they are typically given after surgery and alongside checkpoint inhibitors, not instead of standard care.

References

  1. Bioengineer.org. Review Finds Personalized Neoantigen Vaccines Can Improve Early Disease Outcomes. November 2026.
  2. Moderna and Merck. Phase 2b KEYNOTE-942 trial of mRNA-4157 (V940) plus pembrolizumab in high-risk melanoma. Company announcements, 2023.
  3. National Cancer Institute. Cancer vaccines fact sheet.